IBIsrael Barco

Israel Barco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Israel Barco has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vaccine efficacy to prevent severe COVID-19 in a cohort of breast cancer patients. brief report

    by Israel Barco, Manel Fraile, Marc Garcia, Claudia Mitru, Antonio García, Carol Chabrera

    Background Breast cancer patients, particularly those with stage IV disease, on immunosuppressive therapy, or with comorbidities, may have an impaired immune response to vaccination. This raises concerns about their vulnerability to severe COVID-19. This study evaluated the effectiveness of COVID-19 vaccination in preventing severe disease in breast cancer patients. Methods We conducted a retrospective cohort study of 2,470 patients with invasive breast cancer from our institutional database (January 2020 to January 2024). COVID-19 cases were confirmed by RT-PCR or lateral-flow test. Patients were considered vaccinated if they had received at least one dose within the previous 12 months. Severe COVID-19 was defined as hospitalization for more than 24 h or death from the disease. We analyzed outcomes using a binomial logistic regression model adjusted for potential confounders (age > 85, comorbidities, BMI > 35, stage IV cancer, chemotherapy, and care home residence). Vaccine efficacy (VE) was calculated as 100 × (1 – adjusted odds ratio). Results Seventy-eight patients developed severe COVID-19, including 20 fatalities. Vaccinated patients had significantly lower odds of severe disease (adjusted odds ratio: 0.027; VE: 97.3%). Comorbidities and care home residence were also associated with increased risk. In a sub-analysis of cases after vaccine availability (N = 2,437), the adjusted odds ratio was 0.073 (VE: 92.7%), with comorbidities remaining the only significant non-vaccine risk factor. Vaccination uptake in the cohort was high (91.5%). Conclusions COVID-19 vaccination was highly effective at preventing severe disease in breast cancer patients, including those receiving active cancer treatment. The vaccine's efficacy was comparable to, or even higher than, that observed in the general population, suggesting that breast cancer and its treatment do not substantially impair the protective immune response.

  • Can intraoperative sentinel node fine-needle aspiration biopsy replace sentinel node biopsy in early-stage breast cancer patients undergoing breast-conserving surgery?

    by I. Barco, A. García, E. Vallejo, M. Torras, X. Tarroch, M. Ysamat, M. Fraile

    Background Sentinel Node Biopsy (SNB) side effects could be avoided if the sentinel node (SN) is sampled but not removed using intraoperative fine-needle aspiration biopsy (FNAB). In a previous study, we demonstrated the feasibility of this technique. The goal of our current research is to evaluate its potential as an alternative to SNB in node-negative patients undergoing breast-conserving surgery. Patients and methods We studied 153 cases referred to our Breast Unit for treatment involving conservative breast surgery and SNB. Patients receiving neoadjuvant chemotherapy were excluded. We assessed the sensitivity, specificity, and negative predictive value (NPV) of intraoperative SN-FNAB by comparing it with histopathology results and the need for subsequent axillary lymph node dissection (ALND) across three levels of analysis: direct pathologic comparison, exclusion of micrometastases, and exclusion of up to two involved sentinel nodes. Results In 81.7% of cases, samples were suitable for cytologic analysis. Both sensitivity and NPV reached 100% in the third level of analysis. No negative cases showed tumor involvement beyond the sentinel node. Positive FNAB results were associated with a higher likelihood of ALND and greater axillary tumor burden.


  • Low versus null HER2 tumour expression in “HER2-negative” breast cancer: long-term outcomes based on phenotypes

    by Israel Barco, Clarisa González, Marc García-Font, Antonio García Fernández, Manel Fraile, Xavier Tarroch, Xavier Morlius, Mcarmen Vidal, Sonia González, Claudia B. Mitru, et al.

    Background Two new categories of breast cancer (BC) have been proposed among HER2-negative patients: HER2 0 + and HER2-low breast cancer. We combined these two categories with Perou’s classification. We aimed to identify potential differences in clinicopathological features and prognosis using a new, unofficial classification: Luminal A HER2 0 + , Luminal A HER2-Low, Luminal B HER2 0 + , Luminal B HER2- Low, Triple Negative HER2 0 + , and Triple Negative HER2-Low. Patients and methods We conducted a retrospective analysis of our database from January 1, 2005, to December 31, 2018. Cox Regression served as the basis for our study. Results We identified 1704 BC tumor cases from 1,639 HER2-negative patients (65 had bilateral BC). Among these, 608 cases were HER2 0 + , and 1096 were HER2-Low (aggregate). The median follow-up period was 120 months after surgery. None of the patients received anti-HER2 therapy. Case distribution was as follows: Luminal A HER2 0 + : 259. Luminal A HER2-low: 501. Luminal B HER2 0 + : 219. Luminal B HER2-low: 499. Triple-Negative HER2 0 + : 130. Triple-Negative HER2-low: 96. There was a 12.2% excess in the Triple Negative rate in the HER2 0 + group, compared with the HER2 Low group (aggregate), which was highly significant (Chisquare, p < 0.01). Although the HER2 0 + versus HER2 Low Hazard Ratio (HR) for Specific Mortality was of borderline significance:1.39 (IC 1.00–1.92, p = 0.049), the TN imbalance complicated a direct comparison between the two groups. After stratification using the noncanonical classification, the HR was highly significant, but only for the Luminal A subtype: 2.28 (IC 1.09–4.36, p = 0.028). Comments In the noncanonical classification, the effect of the unbalanced Triple-Negative proportions disappeared, and a significant finding emerged: HER2 0 + status had a negative prognostic influence exclusively in Luminal A patients.

  • Open Access

    Strict versus Liberal Use of Sentinel Node Biopsy in Breast Cancer Surgery: Any Clinical Outcome Differences? A 20-Year Clinical Experience

    by Israel Barco, Marc García-Font, Antonio García-Fdez, Manel Fraile, Elena Vallejo, Mcarmen Vidal, Sonia González, Clarisa González, Claudia Beatriz Mitru, Oriol Porta, et al.

    Introduction: As applied to early breast cancer (BC) patients, sentinel node biopsy (SNB) has undergone major changes over the years, especially concerning the widening of indication criteria or skipping systematic axillary lymph node dissection (ALND) after a positive SN. We aimed to ascertain whether a strict versus a more liberal use of SNB resulted in different clinical outcomes in our clinical experience. Methods: We studied consecutive BC patients undergoing SNB between January 1, 2000, and March 31, 2020. There were 1,587 patients and 1,634 SNB procedures. Cases were divided into two study groups: the “strict” SNB group (unifocal tumors up to 35 mm in which ALND was always performed for a positive SN, amounting to 1,183 SNBs), and the “liberal” SNB group (extended tumor size up to selected T3 cases, as well as multifocal or bilateral disease, and patients with previous contralateral BC, not always followed by ALND after a positive SN, amounting to 451 SNBs). Patients were closely followed up to the end of the study. Results: Clinico-pathological variables were strikingly different between study groups, with the liberal group showing a higher risk profile. Cox regression analysis for disease recurrence did not show significant differences in axillary, lymph node, or locoregional recurrence rates or distant relapse. There were no differences in survival between groups. Conclusion: It seems reasonable to adopt the liberal SNB approach, as the goal of surgical management in early BC patients must be attaining optimal locoregional disease control, no matter the differences in distant metastatic spread rates across different BC risk profiles.

  • Intraoperative Sentinel Node Fine-Needle Aspiration Biopsy as a Substitute for Whole Sentinel Node Excisional Biopsy in Breast Cancer Patients. Initial Report

    by Israel Barco, Antonio García-Fdez, Elena Vallejo, Xavier Tarroch, Montse Ysamat, Cinthya J. Báez, Manel Fraile


  • Short term effects of an initial COVID-19 outbreak on breast cancer care. A brief report

    by Israel Barco Nebreda, Antonio García-Fernández, Lidia Menchen Palau, Nuria Giménez Gómez, Manel Fraile López-Amor

  • Short term effects of an initial COVID-19 outbreak on breast cancer care. A brief report

    by Israel Barco Nebreda, Antonio García-Fernández, Lidia Menchen Palau, Nuria Giménez Gómez, Manel Fraile López-Amor

  • Breast cancer patients developing distant metastasis at follow‐up: Mortality‐related factors

    by Israel Barco, Marc Garcia‐Font, Antonio García‐Fernández, Manel Fraile, Nuria Giménez, Sonia González, Elena Vallejo, Patricia Zarco, Clarisa González, Larrañaga Itziar, et al.

    Click on the article title to read more.


  • Factors associated with the development of distant metastases in breast cancer patients—A regression model predicting organ relapse

    by Israel Barco Nebreda, Carolina Chabrera, Antonio García‐Fernández, Nuria Giménez, Manuel Fraile, Sonia González, Elena Vallejo, Jose María Lain, Mcarmen Vidal, Clarisa Gonzalez, et al.

    Click on the article title to read more.


  • A regression model to predict axillary high tumor burden in sentinel node‐positive breast cancer patients

    by Israel Barco, Marc García‐Font, Antonio García‐Fernández, Nuria Giménez, Manuel Fraile, Sonia González, Elena Vallejo, Jose María Lain, Mcarmen Vidal, Clarisa González, et al.